Vape makers turn to ’Made in America’ credentials amid Trump’s tariffs, crackdown

70% of U.S. vape sales are unlicensed per BAT, in a roughly $12 billion U.S. market, while China-to-U.S. vape shipments exceeded $4 billion in 2025. Since October at least eight new vape brands have promoted 'Made in America' credentials amid a Trump administration crackdown and tariff pressure, and the FDA has licensed only 41 vapes. Analysts and industry sources warn this rebranding or partial onshoring could blunt enforcement impact and slow legal-market gains for tobacco incumbents such as BAT, which has lost share.

Analysis

The immediate competitive dynamic is regulatory arbitrage: actors will relabel, repackage, or shift the minimal-value-add (filling, labeling, distribution) onshore to blunt border enforcement while keeping core low-cost manufacturing offshore. That creates a two-tier market where deep-pocketed incumbents face delayed share recovery (we model a 6–18 month drag) while nimble private operators sustain sales by trading margin for regulatory opacity.

Supply-chain secondaries favor domestic co-packers, logistics providers, and any vendor that enables “light onshore” compliance (fill lines, serialization, U.S. contractual domiciles). Expect capex and opex divergence: compliant firms face multi-point PMTA-style costs and legal overheads, while evasive players incur modest fill-line capex but higher regulatory risk; this widens operating-margin dispersion by several hundred basis points over 12–24 months.

Key catalysts that will re-rate the group are binary and fast: a focused customs/FDA guidance closing the reflagging loophole (0–90 days) or an enforcement surge will compress illicit supply quickly; conversely, absence of clear enforcement or judicial rulings favoring label-based jurisdiction will allow the status quo to persist and push remediation timelines to 18+ months. The consensus underappreciates the speed at which packaging/ownership structures can be altered — market reaction will be choppy, making options-structured trades preferable to outright directional exposure.

Key Decisions for Investors

• Short BTI (British American Tobacco) via 6–12 month puts or a 1:1 pair (short BTI / long APP) — thesis: delayed share recovery and remediation costs. Target 15–25% downside over 6–12 months; cut losses at a 10% adverse move or on a confirmed FDA guidance narrowing reflagging in <90 days.
• Long APP (AppLovin) equity or 3–6 month call spread — thesis: near-term uplift from shifting brand messaging and digital ad reallocation toward 'domestic' campaigns. Target 15–30% upside in 3–6 months; downside limited to advertising pullback risk — size at 2–4% portfolio.
• Long SMCI (Super Micro) 12–18 month call spreads — thesis: incremental demand for on-premise/edge compute and factory automation from reshoring of fill/assembly and serialization. Expect 20–40% upside if adoption accelerates; hedge with 1/2 notional short-dated puts to fund cost if volatility manifests.
• Event monitor: set alert for FDA/customs statement on country-of-origin enforcement and quarterly shipment data for China→US vaping hardware. If guidance narrows loophole within 90 days, trim shorts and rotate into compliant incumbents; if silence persists at 90+ days, add to shorts selectively.